Cargando…
Monitoring response to a clinically relevant IDH inhibitor in glioma—Hyperpolarized (13)C magnetic resonance spectroscopy approaches
BACKGROUND: Mutant isocitrate dehydrogenase (IDHmut) catalyzes 2-hydroxyglutarate (2HG) production and is considered a therapeutic target for IDHmut tumors. However, response is mostly associated with inhibition of tumor growth. Response assessment via anatomic imaging is therefore challenging. Our...
Autores principales: | Hong, Donghyun, Kim, Yaewon, Mushti, Chandrasekhar, Minami, Noriaki, Wu, Jing, Cherukuri, Murali Krishna, Swenson, Rolf E, Vigneron, Daniel B, Ronen, Sabrina M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681661/ https://www.ncbi.nlm.nih.gov/pubmed/38024238 http://dx.doi.org/10.1093/noajnl/vdad143 |
Ejemplares similares
-
Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma
por: Jones, Lindsey E, et al.
Publicado: (2020) -
IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
por: Zhang, Lei, et al.
Publicado: (2018) -
Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
por: Alghamri, Mahmoud S, et al.
Publicado: (2020) -
Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures
por: Verheul, Cassandra, et al.
Publicado: (2021) -
Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression
por: Givechian, Kevin B, et al.
Publicado: (2020)